Current Equity Capital

According to a new enterprise valuation conducted by Stonebridge Advisory Inc., a third-party appraisal firm based in California, Stramsen Biotech Inc. is valued at $19 billion as of February 18, 2026. This comprehensive analysis accounts for several critical factors, including the current state of the pharmaceutical industry, the strength of the Stramsen brand, and our status as a venture-backed enterprise. The valuation also considers our FDA progress, management expertise, financial forecasts, and market size, alongside a comparative analysis of our drug candidate portfolio against industry peers.

As of February 2026, Stramsen Biotech Inc. maintains a robust equity capital structure designed to support its ambitious growth plans. The company has authorized 750 million shares, with approximately 229,041,217 shares currently outstanding. Based on the most recent valuation of $19 billion, our share price in the private market stands at approximately $85 per share. This valuation reflects the market's confidence in our innovative biotech solutions and significant potential for future expansion.

Our substantial market capitalization and share structure provide the financial flexibility necessary to pursue cutting-edge research and development initiatives. This strong financial foundation positions Stramsen Biotech Inc. to address critical challenges in the biotechnology and pharmaceutical sectors. We remain dedicated to the advancement of healthcare solutions that aim to improve patient outcomes on a global scale.

It is important to note that the information provided is accurate as of February 2026. Given the dynamic nature of the biotech industry and financial markets, these figures are subject to change over time. We are committed to transparency and will update this information regularly; for the most current data regarding our outstanding shares or share price, please contact our investor relations team.

Our robust financial position enables us to tackle some of the most pressing issues in healthcare, including:

Developing innovative treatments for rare diseases.
Advancing personalized medicine technologies.
Improving drug delivery systems for enhanced efficacy.
Exploring novel approaches to combat antibiotic resistance.

By leveraging our strong capital structure, Stramsen Biotech Inc. is well-positioned to drive meaningful advancements in these areas. We are focused on revolutionizing patient care and addressing unmet medical needs through rigorous science and strategic investment. Our ongoing mission is to transform the landscape of modern medicine through persistent innovation.